259 related articles for article (PubMed ID: 29858106)
41. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
42. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
Lai J; Garcia-Tizon Larroca S; Peeva G; Poon LC; Wright D; Nicolaides KH
Fetal Diagn Ther; 2014; 35(4):240-8. PubMed ID: 24853452
[TBL] [Abstract][Full Text] [Related]
43. Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia, and normal pregnancy.
Aldika Akbar MI; Herdiyantini M; Aryananda RA; CIninta N; Wardhana MP; Gumilar KE; Wicaksono B; Ernawati ; Sulistyono A; Aditiawarman ; Joewono HT; Nadir Abdullah ; Dekker G; Dachlan EG; Dikman Angsar M
Hypertens Pregnancy; 2018 Nov; 37(4):175-181. PubMed ID: 30277426
[TBL] [Abstract][Full Text] [Related]
44. Association of increased cord blood soluble endoglin with the development of bronchopulmonary dysplasia in preterm infants with maternal preeclampsia.
Kim DH; Shin SH; Kim EK; Kim HS
Pregnancy Hypertens; 2018 Jul; 13():148-153. PubMed ID: 30177044
[TBL] [Abstract][Full Text] [Related]
45. sFlt-1, PlGF, sFlt-1/PlGF ratio and uterine artery Doppler for preeclampsia diagnostics.
Tarasevičienė V; Grybauskienė R; Mačiulevičienė R
Medicina (Kaunas); 2016; 52(6):349-353. PubMed ID: 27940029
[TBL] [Abstract][Full Text] [Related]
46. Angiogenesis biomarkers for the prediction of severe adverse outcomes in late-preterm preeclampsia.
Villalain C; Herraiz I; Cantero B; Quezada S; Lopez A; Simón E; Galindo A
Pregnancy Hypertens; 2020 Jan; 19():74-80. PubMed ID: 31927324
[TBL] [Abstract][Full Text] [Related]
47. VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia.
Trapiella-Alfonso L; Alexandre L; Fraichard C; Pons K; Dumas S; Huart L; Gaucher JF; Hebert-Schuster M; Guibourdenche J; Fournier T; Vidal M; Broutin I; Lecomte-Raclet L; Malaquin L; Descroix S; Tsatsaris V; Gagey-Eilstein N; Lecarpentier E
Hypertension; 2019 Jul; 74(1):145-153. PubMed ID: 31079531
[TBL] [Abstract][Full Text] [Related]
48. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
[TBL] [Abstract][Full Text] [Related]
49. Magnetic blood purification-based soluble fms-like tyrosine kinase-1 removal in comparison with dextran sulfate apheresis and therapeutic plasma exchange.
Rduch T; Arn N; Kinkel J; Fischer T; Binet I; Hornung R; Herrmann IK
Artif Organs; 2023 Aug; 47(8):1309-1318. PubMed ID: 36995348
[TBL] [Abstract][Full Text] [Related]
50. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women.
Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S
J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791
[TBL] [Abstract][Full Text] [Related]
51. Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study.
Contini C; Jansen M; König B; Markfeld-Erol F; Kunze M; Zschiedrich S; Massing U; Merfort I; Prömpeler H; Pecks U; Winkler K; Pütz G
Lipids Health Dis; 2018 Mar; 17(1):49. PubMed ID: 29540222
[TBL] [Abstract][Full Text] [Related]
52. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison.
Andersen LB; Frederiksen-Møller B; Work Havelund K; Dechend R; Jørgensen JS; Jensen BL; Nielsen J; Lykkedegn S; Barington T; Christesen HT
J Am Soc Hypertens; 2015 Feb; 9(2):86-96. PubMed ID: 25600419
[TBL] [Abstract][Full Text] [Related]
53. [Different effects of pravastatin on sFlt-1, PlGF and VEGF in different preeclampsia-like mouse models].
Xiang QQ; Yang Z; Huai J; Wang GJ
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):601-607. PubMed ID: 31550776
[No Abstract] [Full Text] [Related]
54. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
[TBL] [Abstract][Full Text] [Related]
55. Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.
Gurnadi JI; Mose J; Handono B; Satari MH; Anwar AD; Fauziah PN; Yogi Pramatirta A; Rihibiha DD
BMC Res Notes; 2015 Oct; 8():534. PubMed ID: 26434493
[TBL] [Abstract][Full Text] [Related]
56. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
57. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia.
van Helden J; Weiskirchen R
Clin Biochem; 2015 Nov; 48(16-17):1113-9. PubMed ID: 26129879
[TBL] [Abstract][Full Text] [Related]
58. Preeclampsia and superimposed preeclampsia: The same disease? The role of angiogenic biomarkers.
Costa RA; Hoshida MS; Alves EA; Zugaib M; Francisco RP
Hypertens Pregnancy; 2016 May; 35(2):139-49. PubMed ID: 26930132
[TBL] [Abstract][Full Text] [Related]
59. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
[TBL] [Abstract][Full Text] [Related]
60. Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia: a pilot study.
Raio L; Bersinger NA; Malek A; Schneider H; Messerli FH; Hürter H; Rimoldi SF; Baumann MU
J Hypertens; 2019 May; 37(5):1012-1017. PubMed ID: 30882594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
